A Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Cystic Fibrosis

Trial Profile

A Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Cystic Fibrosis

Discontinued
Phase of Trial: Phase III

Latest Information Update: 11 May 2017

At a glance

  • Drugs Ataluren (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions
  • Sponsors PTC Therapeutics
  • Most Recent Events

    • 22 Mar 2017 This trial has been completed in France as per European Clinical Trials Database record.
    • 02 Mar 2017 According to a PTC Therapeutics media release, based on the resuts from ACT CF trial (CTP 700244666), company plans to discontinue current clinical development of ataluren in cystic fibrosis, close ongoing extension studies and withdraw its application for marketing authorization in cystic fibrosis in Europe.
    • 02 Mar 2017 Status changed from recruiting to discontinued, according to a PTC Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top